AU2007348944B2 - Immunoreactive glycoprotein GP19 of Ehrlichia canis - Google Patents

Immunoreactive glycoprotein GP19 of Ehrlichia canis Download PDF

Info

Publication number
AU2007348944B2
AU2007348944B2 AU2007348944A AU2007348944A AU2007348944B2 AU 2007348944 B2 AU2007348944 B2 AU 2007348944B2 AU 2007348944 A AU2007348944 A AU 2007348944A AU 2007348944 A AU2007348944 A AU 2007348944A AU 2007348944 B2 AU2007348944 B2 AU 2007348944B2
Authority
AU
Australia
Prior art keywords
antibody
seq
canis
polypeptide
nucleic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2007348944A
Other languages
English (en)
Other versions
AU2007348944A1 (en
Inventor
Christopher Kuyler Doyle
Jere W. Mcbride
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Development Foundation
Original Assignee
Research Development Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39596493&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2007348944(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Foundation filed Critical Research Development Foundation
Publication of AU2007348944A1 publication Critical patent/AU2007348944A1/en
Application granted granted Critical
Publication of AU2007348944B2 publication Critical patent/AU2007348944B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0233—Rickettsiales, e.g. Anaplasma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1246—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Rickettsiales (O)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/29—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Richettsiales (o)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2007348944A 2006-08-31 2007-08-07 Immunoreactive glycoprotein GP19 of Ehrlichia canis Active AU2007348944B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84146506P 2006-08-31 2006-08-31
US60/841,465 2006-08-31
PCT/US2007/075343 WO2008112007A1 (en) 2006-08-31 2007-08-07 Immunoreactive glycoprotein gp19 of ehrlichia canis

Publications (2)

Publication Number Publication Date
AU2007348944A1 AU2007348944A1 (en) 2008-09-18
AU2007348944B2 true AU2007348944B2 (en) 2013-01-10

Family

ID=39596493

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007348944A Active AU2007348944B2 (en) 2006-08-31 2007-08-07 Immunoreactive glycoprotein GP19 of Ehrlichia canis

Country Status (7)

Country Link
US (3) US9605032B2 (enExample)
EP (1) EP2064231B2 (enExample)
JP (2) JP5498164B2 (enExample)
AU (1) AU2007348944B2 (enExample)
CA (1) CA2662246C (enExample)
ES (1) ES2397548T5 (enExample)
WO (1) WO2008112007A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2604855C (en) 2005-04-04 2016-11-01 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infected from vaccinated animals)
US7842474B2 (en) 2005-04-04 2010-11-30 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)
US9605032B2 (en) * 2006-08-31 2017-03-28 Research Development Foundation Immunoreactive glycoprotein GP19 Ehrlichia canis
US8784828B2 (en) 2007-05-04 2014-07-22 The Ohio State University Research Foundation Ehrlichia ewingii proteins, nucleic acids, and methods of their use
US7964366B2 (en) * 2007-09-21 2011-06-21 Idexx Laboratories, Inc. Methods and compositions for detection of Ehrlichia chaffeensis (VLPT)
WO2009059170A2 (en) 2007-10-31 2009-05-07 Idexx Laboratories, Inc. Ehrlichia canis diva (differentiate infection from vaccinated animals)
GB2467529B (en) 2009-01-30 2013-03-06 Hughes Safety Showers Ltd Frame for a shelter
EP2424880B1 (en) 2009-04-28 2016-07-20 Research Development Foundation Immunoreactive ehrlichia p120/p140 epitopes and uses thereof
US20140162256A1 (en) 2011-03-31 2014-06-12 Yasuko Rikihisa Compositions and methods for the detection of anaplasma platys
EP2925352B1 (en) 2012-12-03 2019-10-02 Ohio State Innovation Foundation Ehrlichial invasin for immunization, diagnosis, and cell delivery
EP3830105A4 (en) 2018-07-27 2022-07-27 Research Development Foundation CHIMERA IMMUNOGENIC POLYPEPTIDES
US20220356231A1 (en) * 2019-07-12 2022-11-10 Research Development Foundation Ehrlichia vaccines and immunogenic compositions
US12226468B2 (en) 2023-06-26 2025-02-18 Research Development Foundation Immunoreactive peptides

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006231473A1 (en) * 2005-04-04 2006-10-12 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355777B1 (en) * 2000-04-28 2002-03-12 Research Development Foundation P43 antigen for the immunodiagnosis of canine ehrlichiosis and uses thereof
US9605032B2 (en) * 2006-08-31 2017-03-28 Research Development Foundation Immunoreactive glycoprotein GP19 Ehrlichia canis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006231473A1 (en) * 2005-04-04 2006-10-12 Idexx Laboratories, Inc. Ehrlichia canis DIVA (differentiate infected from vaccinated animals)

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE UniProt [Online] 27 September 2005 (2005-09-27), "Major outer membrane protein p19." retrieved from EBI accession no. UNIPROT:Q3YSZ1 Database accession no. Q3YSZ1 *
MCBRIDE J W ET AL: "Kinetics of antibody response to Ehrlichia. canis immunoreactive proteins" INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY. WASHINGTON, vol. 71 "no. 5, 1 May 2003, pages 2516-2524, *

Also Published As

Publication number Publication date
US20170173136A1 (en) 2017-06-22
US9814768B2 (en) 2017-11-14
EP2064231B2 (en) 2020-08-26
US20150338406A1 (en) 2015-11-26
AU2007348944A1 (en) 2008-09-18
ES2397548T5 (es) 2021-05-06
EP2064231A1 (en) 2009-06-03
JP5837917B2 (ja) 2015-12-24
JP5498164B2 (ja) 2014-05-21
WO2008112007A1 (en) 2008-09-18
JP2010502187A (ja) 2010-01-28
US20100330091A1 (en) 2010-12-30
JP2014113149A (ja) 2014-06-26
US9605032B2 (en) 2017-03-28
EP2064231B1 (en) 2012-10-24
CA2662246A1 (en) 2008-09-18
CA2662246C (en) 2016-07-05
ES2397548T3 (es) 2013-03-07
US9605033B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
US11459379B2 (en) Immunoreactive protein orthologs of Ehrlichia canis and E. chaffeensis
US9814768B2 (en) Immunoreactive glycoprotein GP19 of Ehrlichia canis
US10131705B2 (en) Vaccines and diagnostics for the ehrlichioses

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)